CSE | OTC | FSE

novamentis life science

The Nova Mission

We’re a Canadian-based biotechnology company and global leader in psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. Our mission is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder and fragile X syndrome.

 

Nova is the first company to achieve psilocybin orphan drug
designation
in both the U.S. and European Union for the treatment of
fragile X syndrome, the leading genetic cause of symptoms
related to autism spectrum disorder.

This provides us with financial benefits, market exclusivity,
research assistance and access to grants.

FDA EMA

 

Autism Spectrum Disorder and Fragile X Syndrome Observational Study

 

Learn More

Latest News

Nova Mentis Completes Production of Psilocybin Microdose Capsules
Company Plans to Submit Clinical Trial Application in Canada

Vancouver, British Columbia – September 15, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has completed production

 

Nova Mentis to Present Promising Psilocybin Microdose Data at 18th NFXF International Fragile X Conference

Vancouver, British Columbia – July 11, 2022 Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it will be discussing the therapeutic potential of oral microdose psilocybin for the treatment of autism spectrum disorder (ASD) and fragile X syndrome (FXS) during a...